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Maternal immune activation (MIA) is a potential risk factor for autism spectrum disorder (ASD) and schizophrenia (SZ). In
rodents, MIA results in changes in cytokine profiles and abnormal behaviors in the offspring that model these neuropsychiatric
conditions. Given the central role that mitochondria have in immunity and other metabolic pathways, we hypothesized that MIA
will result in a fetal imprinting that leads to postnatal deficits in the bioenergetics of immune cells. To this end, splenocytes from
adult offspring exposed gestationally to the viralmimic poly(I:C)were evaluated formitochondrial outcomes. A significant decrease
in mitochondrial ATP production was observed in poly(I:C)-treated mice (45% of controls) mainly attributed to a lower complex
I activity. No differences were observed between the two groups in the coupling of electron transport to ATP synthesis, or the
oxygen uptake under uncoupling conditions. Concanavalin A- (ConA-) stimulated splenocytes from poly(I:C) animals showed
no statistically significant changes in cytokine levels compared to controls. The present study reports for the first time that MIA
activation by poly(I:C) at early gestation, which can lead to behavioral impairments in the offspring similar to SZ and ASD, leads
to long-lasting effects in the bioenergetics of splenocytes of adult offspring.
1. Introduction
The most recent estimates indicate that the prevalence of
autism spectrum disorders (ASD) in the United States has
raised to 1 in 54 boys and 1 in 252 girls [1]. Although increased
awareness and changes in diagnostic criteria have been pro-
posed as the major contributors to this increased prevalence
[2], as of today, the etiopathology of disorders like ASD and
schizophrenia (SZ) remains largely unknown.
Several studies have suggested that impaired mitochon-
drial function and altered energy metabolism in individuals
with ASD may contribute to their social and cognitive
deficits [3–5], and recent reports indicate the presence of
mitochondrial dysfunction (MD) in brain, skeletal muscle,
and peripheral blood mononuclear cells (PBMC) from chil-
dren with ASD.TheMD in ASD is generally characterized by
lower complex I activity accompanied, in a subset of cases, by
deficits in other complexes [6–8].
Beside their critical role in a number of pathways, span-
ning from ATP production (via oxidative phosphorylation),
one-carbon metabolism regulation, heme biosynthesis, fatty
acid catabolism, and branched chain amino acid metabolism
[9], mitochondriamay also impact the immune response and
vice versa [10–12]. For example, human neutrophilmitochon-
dria are involved in several functions such as chemotaxis,
respiratory burst activity, maintenance of cell shape, and
apoptosis [13–17]. Furthermore, neutrophil phagocytosismay
involve the incorporation of some mitochondrial proteins
into the phagosome [18]. In addition, mitochondria can be
involved in the immune response by providing part of the
metabolic pathway for Gln, in a process named “glutaminoly-
sis” [19, 20]. Interestingly, Gln is implicated in the expression
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of NADPH oxidase components, cytokine production in
lymphocytes, and macrophage, and as a provider for sub-
strates required for nucleic acid synthesis [21–25]. Taken
together, these lines of evidence unveil a link between
mitochondria and immune response [10–12]. Indeed, deficits
in bioenergetics have been reported in lymphocytes from
children with ASD enrolled in the case-control population-
based Childhood Autism Risk Genetics and Environment
(CHARGE) Study [26, 27]. Children with ASD in this study
display a number of immune dysfunctions including abnor-
malities in monocytes, T cells and NK cell responses [28].
These observations suggest the presence of a genetic back-
ground that results in a distinct immune profile in responses
to a variety of triggers, among them psychological stressors,
exposure to chemical triggers, and infectious agents [29, 30].
Considering that (i) mitochondria are inherited mater-
nally via oocyte, (ii) maternal diet or immune activation
during pregnancy has an impact on fetal metabolic and
immune programming [31–33], and (iii) offspring born to
pregnant mice injected with poly(inosinic:polycytidylic acid)
(poly(I:C)), a synthetic double-stranded RNA that mimics
viral infection via activation of Toll-like receptor-3 (TLR3), at
embryonic day 12.5 (E12.5), display core behavioral symptoms
of ASD [34, 35] and SZ [34], it is hypothesized that prenatal
exposure of mothers to an immunogenic response, that
is, poly(I:C) elicits changes in mitochondrial function in
splenocytes from progeny lasting into adulthood. Exposure
to TLR ligands can lead to maternal hypertension, vascular
dysfunction, and proteinuria in pregnant animals but not in
nonpregnant animals [36–38] suggesting the occurrence of
a differential immune response/pathway during pregnancy.
Differences are also evident between pregnant individuals
with human placentas and patients with preeclampsia show-
ing greater expression of TLR3, along with TLR2, TLR4, and
TLR9, compared to nonpreeclampsia mothers [39, 40].These
data suggest that TLR signaling may be involved in placental
deficiencies/abnormalities that may provide a framework
for altered fetal programming. Of note, trophoblastic inclu-
sions, which are also observed in preeclampsia and other
placental defects, were reported to be increased in placenta
from mothers of children with ASD compared to controls
[41]. Furthermore, maternal exposure to various pathogens,
including viruses, significantly increases the risk for ASD and
SZ [42–48]. Considering that maternal exposure to various
pathogens is associated with ASD and SZ, the critical link
between prenatal maternal infection and postnatal brain
and behavioral pathology seem to be the maternal immune
response, including cytokine production [47, 49–54], which
may contribute to the fetal imprinting of the neuroimmune
response and, possibly, mitochondria-mediated metabolic
responses. Although it is already known that upon poly(I:C)
injection, the induction of maternal cytokines alters the
expression of several cytokines in the fetal brain (with only
IL-1𝛽 remaining elevated at 24 h [53] with only a few changes
during adulthood), it is unknown ifmaternal immune activa-
tion (MIA) also causes chronic changes in the bioenergetics
of immune cells (such as splenocytes) of adult offspring.
In this study, we sought to determine whether MIA in
pregnant dams alters mitochondrial function in splenocytes
from affected offspring. To test this, dams were exposed to
poly(I:C) on gestational day 12.5 to induce MIA. This stage
of gestation correlates with the late first trimester in humans
[55], coincidental with the time that infections are most
closely linked to increased incidence of ASD and SZ [47, 48].
The present study reports for the first time that MIA activa-
tion by poly(I:C) at early gestation, which can lead to impair-
ments in multiple psychological domains, is associated with
mitochondrial changes in immune the cells of adult offspring.
2. Materials and Methods
2.1. Animals. Male and female C57BL/6J (Jackson Labora-
tory, Sacramento, CA, USA) mice were bred and maintained
by the Center for Laboratory Animal Research, at University
of California, Davis, and maintained at ambient room tem-
perature on a 12 h light/dark cycle (lights on at 06:00 h). Food
and water were provided ad libitum. All procedures were
performed with approval by the Institutional Animal Care
and Use Committee, University of California, Davis, and in
accordance with the guidelines provided by the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals.
2.2. Treatment and Behavioral Assessment. Mice were mated
overnight and females were checked daily for the presence of
seminal plugs, noted on gestational day 0.5 (G0.5). On G12.5,
pregnant femalemicewereweighed and injectedwith a single
dose (20mg/kg; i.p.) of poly(I:C) (Sigma Aldrich, St Louis,
MO, USA) or saline vehicle (SHAM) as previously described
[35]. Each dam was returned to its cage and left undisturbed
until the birth of its litter. All mice pups remained with the
mother until weaning on postnatal day 21, at which timemice
were group-housed 3-4 per cage with same-sex littermates.
Mice born from poly(I:C)-treated dams exhibited autism-
like behavioral deficits including reduced social approach,
increased ultrasonic vocalizations, and repetitive marble
burying behaviors [35].
2.3. Splenocyte Isolation. One week following behavioral
testing, 12 wk old mice were sacrificed by cervical dislocation
and spleens were collected for tissue processing.While spleen
is constituted by a variety of cells relevant to the immune
response (including T- and B-lymphocytes, dendritic cells,
and macrophages), it has recently been shown that spleens
from the offspring of MIA mice elicited by poly(I:C) provide
a more homogeneous preparation enriched in granulocytes
compared to the preparation obtained fromwhole blood [56].
Briefly, spleens were homogenized into single cell suspen-
sions by gently pushing them through a 100𝜇m nylon mesh
filter (Fisher Sci) into PBS at 4∘C. Cells were then pelleted,
and RBCs were lysed using ACK lysis buffer according to the
manufacturer’s instructions (Gibco). Cell suspensions were
kept on ice until analyzed for mitochondrial activity. Cell
viability was determined by trypan blue staining and found
to be about 90%.
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2.4.Mitochondrial Activities. Theoxygenuptake of intact cell
suspensions (106 cells/mL) obtained as described above was
measured by using a Clark-typeO
2
electrode fromHansatech
(King’s Lynn, UK) at 22∘C. Cells were incubated in the
presence of 5mM glucose in calcium and magnesium-
supplemented HBSS buffer without phenol red at 20–22∘C.
NADH, succinate, and cytochrome oxidase activities were
evaluated under phosphorylating conditions as described
before [6, 30]. To this end, cells were permeabilized with a
controlled treatment with digitonin [57] by adding 60 𝜇g/mL
2x recrystallized digitonin for 2min. The solubilization was
stopped by the addition of 1mg/mL BSA. Oxygen consump-
tion rates were evaluated in the presence of 1mM ADP plus
1mM malate-10mM glutamate followed by the addition of
5 𝜇M rotenone; 10mM succinate followed by the addition
of 3.6 𝜇M antimycin A, and 10mM ascorbate and 0.2mM
N,N,N󸀠,N󸀠-tetramethyl-p-phenylenediamine followed by the
addition of 1mM KCN.
2.5. Statistical Analyses. All mitochondrial experiments were
run in triplicates. Mitochondrial data were expressed as
mean ± standard error. Student’s two-tailed 𝑡-test was used
to evaluate the differences between offspring of poly(I:C)-
treated and SHAM-treated dams.
3. Results and Discussion
3.1. Deficits in Complex I in Splenocytes from Mice Gestation-
ally Exposed to Poly(I:C). Splenocytes from adult mice born
to either SHAM- or poly(I:C)-treated dams were isolated for
mitochondrial function testing. Given that most of the oxy-
gen uptake by cells is linked to ATP production via oxidative
phosphorylation, this parameter was evaluated in intact cells
in the presence of glucose (Figure 1(a)). The rate of oxygen
uptake by intact cells from SHAM-treated dams was 0.22 ±
0.03 nmol oxygen × (min × 106 cells)−1. Under the same con-
ditions, this rate was decreased by 36% in poly(I:C)-treated
dams (Figure 1(a)). Addition of oligomycin, an inhibitor of
ATPase, was used to stop the fraction of oxygen utilized
to synthesize ATP via mitochondria. In both groups, more
than 90% of the total oxygen uptake was inhibited by
oligomycin, supporting the previous assumption that most—
if not all—oxygen uptake by these cells was derived from
oxidative phosphorylation. The oxygen uptake resistant to
oligomycin, considered somewhat equivalent to State 4 (non-
phosphorylating mitochondria), was not different between
groups. This result indicated that the proton leak across the
inner mitochondrial membrane was similar in both groups,
suggesting no major mitochondrial membrane damage by
either treatment. Addition of FCCP, an uncoupler of electron
transport and ATP synthesis, increased significantly the basal
oxygen uptake to a similar extent in both groups (2.5- to 3-
fold) with no changes between treatments, suggesting that the
maximum respiratory capacity was similar in both groups.
Coupling between oxygen uptake and ATP production
was evaluated by the respiratory control ratio in intact
cells (RCR). Mitochondria from either treatment showed a
significant coupling with glucose as a substrate (with malate-
glutamate, RCR = 3.5 ± 0.4 and 2.7 ± 0.3; with succinate,
RCR = 4 ± 1 and 6.2 ± 0.5, for saline and poly(I:C), resp.)
with no statistical differences between treatment groups.This
result indicated that mitochondria were highly coupled and
provided a means of support for their integrity during the
testing process.
Phosphorylating mitochondria from splenocytes of
SHAM animals in the presence of an NAD-linked substrate
(such as malate) consumed oxygen at a rate of 0.31 ±
0.04 nmol oxygen × (min × 106 cells)−1. Phosphorylating
mitochondria from offspring of poly(I:C)-treated dams
showed a significant decrease in oxygen consumption (by
55%; 𝑃 < 0.01; Figure 1(b)). By adding rotenone, an inhibitor
of Complex I, and succinate, a substrate for complex II, the
segment comprising from complex II to complex V was
evaluated. No differences in terms of oxygen uptake were
observed between controls and poly(I:C) suggesting that the
deficit in offspring of poly(I:C)-treated dams was located at
the level of complex I. Confirming this result, complex IV
activity was not different between treatments (Figure 1(b))
suggesting that mitochondrial mass was equivalent between
groups. However, attempts to directly evaluate complex I
activity were unsuccessful due to the limited amount of
biological material.
The ratios among complexes need to be preserved to
provide suitable oxidation of substrates [58]. To this end,
the ratios of electron transport chain activities indicated
that both treatments allow oxidizing FAD-linked substrates
(such as fatty acids) similarly, whereas a significantly lower
oxidation of NAD-linked substrates (such as glucose) was
evident in the poly(I:C)-treated condition compared to con-
trols (Figure 1(c)). This imbalance in the complexes’ ratios
suggests that splenocytes from offspring of dams exposed to
poly(I:C) use preferentially fatty acids over glucose as their
main substrate for mitochondrial oxidative phosphorylation.
These results are consistent with the MD observed in
lymphocytes from ASD children characterized by lower
complex I activity and accompanied, in some cases, by deficits
in other complexes and/or pyruvate dehydrogenase [6–8].
The cytokine production (IL-1𝛽, IL-6, IL-10, IL-17, and
TNF-𝛼) from ConA-activated splenocytes obtained from
adult offspring of poly(I:C)-treated animals was not different
from that of SHAM-treated animals (see Supplementary
Material available online on http://dx.doi.org/10.1155/2013/
609602). This is consistent with the findings of others utiliz-
ing a similarMIAmodel in which only a handful of cytokines
was still increased in early adulthood (frontal corteces IL-
1𝛼, IL-6, IL-10, and IL-9; cingulate corteces IL-10 and IFN-𝛾;
none in hippocampus or serum [33]).
4. Conclusions
The aim of this study was to evaluate mitochondrial function
in splenocytes from offspring gestationally exposed to an
acute viral mimetic, that is, poly(I:C), to induce MIA. Our
results indicate that the exposure of dams to a single dose
of poly(I:C) at gestational day 12.5 likely triggers a TLR3-
mediated response in themother that is transmitted transpla-
centally to the offspring. In particular, the proinflammatory
cytokine IL-6 has been proved to be a key intermediary in
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Figure 1: Mitochondrial outcomes in splenocytes. Splenocytes from offspring (10–12 weeks old) poly(I:C)-(𝑛 = 8) or saline-(𝑛 = 8) treated
dams at 12.5 gestational day were isolated, and mitochondrial outcomes were tested as described in detail in Section 2. (a) Oxygen uptake
of intact cells was determined using a Clark-type electrode in Hanks balanced salt solution (HBSS) supplemented with 6mM glucose as
substrate. Basal (only glucose), oligomycin (0.2𝜇M), and FCCP (20𝜇M) were added, and the initial rates of oxygen uptake were calculated
and normalized by million cells. (b) Permeabilized cells were tested for their capability to consume oxygen coupled to ATP production by
supplementing the media with malate-glutamate (or NADH oxidase comprised by complexes I–V), succinate with rotenone (or succinate
oxidase comprised by complex II–V), and TMP-ascorbate for cytochrome c oxidase activity (or complex IV). (c) ratio of rates of oxygen
consumption in the presence of various substrates derived from (b).
the behavioral changes observed in the offspring of dams
treated with poly(I:C) [59]. Moreover, blocking IL-6 with
antibodies prevents behavioral changes in the offspring [60],
and poly(I:C)-induced MIA in IL-6 KO does not result in
behavioral changes in the offspring [60]. These data seem to
suggest a role for IL-6 in MIA-induced behavioral changes,
although we cannot exclude other inflammatory agents such
as type 1 interferons which have also been shown to take
part in the response to poly(I:C) [61]. This MIA imprints a
fetal programming that can still be detected during adulthood
characterized by abnormal behaviors resembling those of
ASD [34, 35] and SZ [34] and, biochemically, by a lower
oxidative phosphorylation capacity in mitochondria within
intact cells and isolated mitochondria. This suggests that
prenatal immune changes ensuing the maternal poly(I:C)
administration are likely to imprint the long-lasting changes
in the bioenergetics of the adult offspring splenocytes. While,
at the normal murine fetomaternal interface, immune cells
such as neutrophils, macrophages, and NK cells are assumed
to be excluded from the placenta and localized only in the
decidua [62], treatment with poly(I:C) disrupts this normal
distribution and induces a significant increase in the levels of
proinflammatory cytokines in the placenta and a largemigra-
tion of immune cells, primarily NK cells from the decidua
towards the placenta, invading the spongiotrophoblast and
then the labyrinth [63]. Trophoblasts, which express TLR3
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[63], play a role in coordinating the maternal innate immune
response to infection at the fetomaternal interface [62–64]
and, especially in this case, in response to viral infection.
These results beget the question, what is the link between
lower complex I activity (or lower oxidative phosphorylation)
in the offspring and an acute maternal immune response?
A growing body of evidence is placing mitochondria at the
center of bioenergetics and immune response/inflammation.
Immunity to infection is also dependent on mitochondria
function by regulating the synthesis of both pro- and anti-
inflammatory cytokines [65–69]. More recently, the view that
mitochondria act as a platform facilitating innate immune
responses adds to our understanding of themolecular compl-
exity of sensor and adaptor interactions that promote effective
host defense [11, 70].
Therefore, an emerging concept is that innate immune
signaling is regulated by basic host metabolic functions. For
instance, Toll-like receptor signaling activates mitochondrial
biogenesis during critical illness [71–73], perhaps in response
to increased oxidative damage in host cells [71, 74, 75]. Acute
inflammation is accompanied by increases in inflammatory
cytokines sustained by glycolysis, whereas chronic inflamma-
tion is sustained by less inflammatory cytokines, with more
reparative features fueled mainly by mitochondria-derived
ATP [76]. Thus, in this study, MIA seems to imprint the
immune cells of adult offspringwith thismore glycolytic stage
resembling the influence of an acute inflammation, without
switching back to the less inflammatory response. Without
pointing at cause or consequence, it is interesting to note that
the changes in bioenergetics in the immune cells (and not
their immune response or the immune response in brain or
serum [33]) segregate with the abnormal behaviors observed
in this MIA model [35]. However, a number of studies have
shown differential MIA induction and behavioral responses
depending on the gestational exposure stage [77–79]. This
would suggest the existence of a window of vulnerability to
infection during gestation for the onset of different behavioral
defects, which may be reflected also on the mitochondrial
function of the offspring.
The above effects can be explained by (i) the transfer
of immune cells and/or cytokines from mother to the fetus
at the maternal-fetal interface and (ii) a genetic predisposi-
tion/susceptibility of the offspring that, in association with
maternal viral or bacterial infections, might increase the
risk of long-lasting behavioral and immune changes [35].
Furthermore, we cannot exclude the possibility that the
relatively high doses of poly(I:C) used in this study could
have affected the well-being of the mother and therefore that
of the fetus. For instance, poly(I:C) inhibits the development
of diabetes in the NOD mouse [80] whereas the develop-
ment of diabetes in diabetes-prone BB rats is poly(I:C)-dose
dependent [81–84]. Indeed, a recent report indicated that at
least some nongenetic risk factors are shared between ASD
and SZ, in particular, diabetes, exposure to drugs, nutritional
deficiencies, and infectious agents among others [85].
Considering themechanisms described above, studies are
now needed to clearly identify the key players affected in this
acute viral response in order to evaluate the increase in risk
of either ASD or SZ that is associated with these (and other
[30, 86, 87]) modifiable environmental factors to elicit public
health interventions.
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